Cancer drugs underprescribed in Wales compared to England

March 4, 2014
Cancer drugs underprescribed in Wales compared to England

Patients suffering from cancer in England are up to seven times more likely to be prescribed expensive cancer drugs than fellow sufferers in Wales, a new study assessing the impact of the Cancer Drugs Fund (CDF) has revealed.

Researchers from the University of Bristol compared the prescription of 15 cancer drugs in both countries to show the divide created by the introduction of the CDF in 2010 to help patients in England access certain drugs.

The CDF is money the Government has set aside to pay for that haven't been approved by the National Institute for Health and Care Excellence (NICE) and aren't available within the NHS in England. The scheme was due to end this year, but David Cameron has pledged £400 million to keep it running.

The governments of Scotland, Wales and Northern Ireland decide on how they spend money on health and so far haven't decided to run a similar programme.

There are currently over 70 drugs available through the CDF, with over 38,000 patients in England receiving them in the past three years. Reasons for NICE not approving them could be because the drugs haven't been looked at yet or because NICE have said they are not cost-effective.

For this study, researchers analysed data from hospital pharmacies in both England and Wales from August 2007 to December 2012, to capture data from before and after the establishment of the Cancer Drugs Fund.

The 15 drugs were selected to represent different categories of NICE approval – recommended, not recommended and not appraised.

The results, published in the British Journal of Cancer, show that drugs recommended by NICE were not prescribed any more in England than in Wales following the introduction of the Cancer Drugs Fund.

However, drugs that were rejected by NICE because they were not good value for money were prescribed up to seven times more often in England than in Wales.

Unexpectedly, the three most recently launched drugs (Pazopanib, Bendamustine and Abiraterone), which were awaiting appraisal by NICE at the time of the introduction of the Cancer Drugs Fund and have since been approved, were adopted faster in Wales than in England.

This suggests that doctors in England have been slower to adopt newer drugs which do provide good value for money.

The research was led by Dr Charlotte Chamberlain, an NIHR Doctoral Research Fellow from the University of Bristol's School of Social and Community Medicine. She said: "There's been much debate surrounding the Cancer Drugs Fund. The vast majority of Cancer Drugs Fund drugs do not cure the cancer, but may extend life or improve symptoms in some people.

"The high cost of these drugs means that the NHS cannot afford other treatments and therefore, critics argue that public money is being spent inefficiently. It's also been controversial because people perceive that the fight against cancer is being prioritised over other diseases.

"Our research has highlighted that the CDF has created an inequality between cancer sufferers in England and those in Wales. This raises ethical, moral, financial and policy concerns."

Explore further: Tighten up value for money appraisals of new drugs in England, urges DTB

More information: "Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales." C Chamberlain, S M Collin, P Stephens, J Donovan, A Bahl and W Hollingworth. British Journal of Cancer advance online publication 25 February 2014; DOI: 10.1038/bjc.2014.86

Related Stories

Tighten up value for money appraisals of new drugs in England, urges DTB

December 14, 2013
The body that appraises the clinical and cost effectiveness of new drugs in England would do well to take a leaf out of its sister organisations' books in Wales and Scotland, says an editorial in the Drug and Therapeutics ...

Lack of support for 'ring-fencing' cancer drugs fund revealed

August 16, 2012
The public oppose the cancer drugs fund but support the new pricing system for branded medicines, according to a new study.

Re-thinking cancer treatment

November 18, 2013
A new treatment approach for tackling cancer of the food pipe (oesophagus) has been developed by researchers at Cardiff and Velindre NHS Trust.

Research could help minimize unnecessary exposure to drugs with potential side effects

February 25, 2014
Patients with advanced non-small cell lung cancer (NSCLC) often suffer the challenging side effects of drug regimens that may not have any impact, says Jayson Parker, PhD, a lecturer at U of T Mississauga. Meanwhile pharmaceutical ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.